Registered Tanzania · TMDA

Simparica 20 mg

Sarolaner 20 mg/6 mL

TAN 25 VM 0095 Tablets, Chewable INN generic

What it does

Sarolaner is a medication used to treat specific parasite infestations in pets.

Commonly used for: flea infestations (flea control), tick infestations (tick control)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
TAN 25 VM 0095
Registration date
2025-02-13
Expiry date
2030-02-12
Status
Registered/Compliant
Active ingredient
Sarolaner 20 mg/6 mL
Dosage form
Tablets, Chewable
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Zoetis
Applicant / LTR
Zoetis Belgium SA
Country of origin
USA
Manufacturer location
10 Sylvan Way, Parsippany, NJ 07054, USA

Source: Tanzania Medicines and Medical Devices Authority · fetched 2026-03-11 23:51:49 · updated 2026-09-17 03:00:44

Disclaimer: This information is sourced from Tanzania Medicines and Medical Devices Authority (Tanzania). Always consult a qualified healthcare professional before using any medication.

About this medicine

Sarolaner is a medication used to treat specific parasite infestations in pets.

What it treats

  • flea infestations (flea control)
  • tick infestations (tick control)

How it works

It works by disrupting the nervous system of the parasites, effectively killing them.

Who it's for

Sarolaner is intended for use in dogs and cats to help manage and prevent parasite infestations.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: sarolaner

BNF-referenced

Sarolaner is an insecticide and acaricide used in veterinary medicine, primarily for the treatment and prevention of flea and tick infestations in dogs and cats. It belongs to the isoxazoline class of compounds, which act by disrupting the nervous system of parasites, leading to their death. Sarolaner is administered orally and is well-absorbed, providing a long duration of action against ectoparasites.

Indications

  • Treatment of flea infestations in dogs and cats
  • Treatment of tick infestations in dogs and cats
  • Prevention of flea and tick infestations

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for paediatric patients.

Adults: For dogs, the recommended dosage is 2 to 4 mg/kg body weight, administered once monthly. For cats, the dosage is similar, with emphasis on accurate weight measurement to ensure proper dosing.

Mechanism of action

Sarolaner exerts its effects by inhibiting the function of ligand-gated chloride channels, specifically the gamma-aminobutyric acid (GABA) and glutamate-gated chloride channels in arthropods. This inhibition leads to hyperexcitation of the nervous system, paralysis, and ultimately death of the fleas and ticks.

Pharmacodynamics

The pharmacodynamic profile of sarolaner indicates that it is highly effective against various ectoparasites. It demonstrates a rapid onset of action, killing fleas within 8 hours and ticks within 12 hours of administration. The drug's efficacy is primarily due to its strong binding affinity for the target ion channels, which results in prolonged neurotoxicity in susceptible parasites.

Pharmacokinetics

Sarolaner is well-absorbed following oral administration, with peak plasma concentrations typically reached within 4 to 6 hours. It has a half-life of approximately 18 to 21 days, allowing for sustained efficacy with monthly dosing. The drug is predominantly metabolized in the liver, with excretion occurring mainly through feces and urine. Its bioavailability is affected by food intake, with higher absorption noted when given with a meal.

Adverse effects

  • Vomiting
  • Diarrhea
  • Hypersensitivity reactions
  • Ataxia
  • Lethargy

Precautions

  • Use with caution in animals with a history of hypersensitivity to sarolaner
  • Not recommended for use in dogs less than 6 months of age or weighing less than 5 kg

Pregnancy

The safety of sarolaner in pregnant dogs has not been established. Use only if the benefits outweigh the risks.

Breast-feeding

The safety of sarolaner in lactating dogs has not been established. Use only if the benefits outweigh the risks.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

  • Chewable tablets

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: sarolaner

PubChem CID 73169092

Molecular formula: C23H18Cl2F4N2O5S

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.